Declaretimi 58 Supports Hf Benefit Of Sglt2 Inhibitors | Latest News RSS feed

Declaretimi 58 Supports Hf Benefit Of Sglt2 Inhibitors - Latest News


DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

CHICAGO, IL—DECLARE-TIMI 58, a trial of the selective sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga; AstraZeneca) in patients with type 2 diabetes and high cardiovascular ri... read more

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes

I think after the DECLARE-TIMI 58 trial we can definitely now say the biggest benefit of the SGLT2 inhibitors is on the prevention of heart failure, and the reduction in major cardiovascular events is ... read more

Diabetes medication reduces risk of heart failure hospitalization

This benefit was seen across the study population, including in patients who did not have a history of heart attack or heart failure ... said Wiviott. "DECLARE-TIMI 58 builds upon two other recent tri... read more

Looking for another news?


Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

The drug did not produce the same mortality benefits seen with competitors in the class. The big news, however, is what heart failure ... SGLT2 inhibitors, appearing in The Lancet appearing less than ... read more


AHA: Reverse Remodeling Plays Role in Jardiance CV Benefit

"These data suggest that the SGLT-2 inhibitor, empagliflozin, promotes early, statistically and clinically significant reverse remodeling which may contribute to the cardiovascular and heart failure b... read more

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018

DECLARE-TIMI 58: a landmark CVOT evaluating CV risk in patients with ... and achieved a statistically-significant reduction in the composite endpoint of hospitalization for heart failure (hHF) or CV d... read more

New CARMELINA Analysis: No Heart Failure Risk With Linagliptin

They add, "These data provide further support that linagliptin may be safely used, without concerns for increasing heart failure ... "I think after the DECLARE-TIMI 58 trial we can definitely now say ... read more

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association ...

Some key exclusion criteria, again, the full list is contained in the NEJM related documents included severe Class 4 heart failure ... years and SGLT2 as a class seem to have that benefit. read more

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular (CV) outcomes trial (CVOT) DECLARE (Dapagliflozin Effect on Card... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us